Table 3 Treatment difficulty and non-adherence among CML patients, according to current CML treatment
Imatinib | Dasatinib | Nilotinib | Imatinib vs. Dasatinib | Imatinib vs. Nilotinib | Dasatinib vs. Nilotinib | ||||
|---|---|---|---|---|---|---|---|---|---|
(N=208) | (N=38) | (N=49) | |||||||
Mean, N | SD, % | Mean, N | SD, % | Mean, N | SD, % | p-value | p-value | p-value | |
Treatment Difficulty | |||||||||
Yes | 40 | 19.23% | 1 | 2.63% | 31 | 63.27% | 0.01 | <.01 | <.01 |
No | 168 | 80.77% | 37 | 97.37% | 18 | 36.73% | 0.01 | <.01 | <.01 |
Non-Adherence | |||||||||
No. Missed Doses | 0.45 | 1.08 | 0.63 | 1.73 | 1.02 | 1.60 | 0.54 | 0.02 | 0.29 |
No. Skipped Doses | 0.41 | 1.53 | 0.53 | 1.83 | 0.73 | 1.62 | 0.72 | 0.21 | 0.58 |
No. Doses Less than Prescribed | 0.10 | 0.52 | 1.05 | 4.78 | 0.47 | 1.46 | 0.23 | 0.08 | 0.47 |